A Phase 1/2 interventional study of Rivaroxaban (Xarelto, BAY59-7939) in Thromboembolism, sponsored by Bayer. Completed at 9 sites in 7 countries. Open to participants aged Up to 6 Months. Per ClinicalTrials.gov, last updated 2018-07-10.
Sponsored by Bayer · Phase 1/2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing rivaroxaban in Thromboembolism — 4 open to participants now, 4 under way, 1 of them phase 3. Rivaroxaban · Thromboembolism.
Among the 17 studies testing rivaroxaban in Thromboembolism, this one is the 16th largest by enrollment, is the only one that started in 2015, is the only one in phase 1/2, and was the 10th registered.
288 studies on the registry are indexed under Thromboembolism; 42 are open to participants now.
Browse Thromboembolism studies →4 of the 17 studies testing rivaroxaban in Thromboembolism are open now, in 4 countries. Recruiting first, the newest first:
Joon Bum Kim · Sites in Korea, Republic of
Ages 19+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Lebanese University · Sites in Lebanon
Ages 18+
Rawalpindi Institute of Cardiology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 32 Thromboembolism studies recruiting now, 23 (72%) set no upper age limit and 4 (13%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: Up to 6 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 9 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 173 across 155 interventional studies indexed under Thromboembolism.
Median enrollment 112 across the 17 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 17 have an industry lead sponsor. The 9 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
15 studies in Thromboembolism by Bayer: none open now, none under way, none of them phase 3. Of 14 finished, 4 (29%) have results posted.
Among the 15 studies in Thromboembolism by Bayer, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 1/2, and was the 11th registered.
Bayer’s Thromboembolism studies by the year they started, since 2002.
2 of the studies testing rivaroxaban in Thromboembolism that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07456085Phase 3Rawalpindi Institute of CardiologyRivaroxaban vs Warfarin in Patients With Mechanical Heart Valves | 2027-04-12 |
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing rivaroxaban in Thromboembolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 15 in Thromboembolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out whether rivaroxaban is safe and effective to use in children age newborn to less than 6 months and how long it stays in the body and how it is used in the body. Safety will be assessed by looking at the incidence and types of bleeding events. There will also be a check for worsening of blood clots.
Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or vitamin K antagonist (VKA) for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a 7-day treatment with an age- and body weight-adjusted three times daily, approximately 8 hours apart oral rivaroxaban dosing to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily. Rivaroxaban will be provided as granules for preparation of an oral suspension (1 mg/mL after re-suspension) using a t.i.d. regimen with 8-hour intervals. An ultrasound will be performed before starting rivaroxaban at treatment day 1 and after the end of rivaroxaban treatment at day 8. The last dose of rivaroxaban treatment will be followed by a 30-day post study treatment period, regardless of the duration of study drug administration. After cessation of rivaroxaban, it is at the investigator's discretion to continue with anticoagulants. The principal safety outcome is the combination of major and clinically relevant non-major bleeding. The efficacy outcome is the composite of all symptomatic recurrent thromboembolism and asymptomatic deterioration in thrombotic burden on repeat imaging. All suspected recurrent thromboembolism, asymptomatic deterioration in thrombotic burden on repeat imaging, deaths, as well as all episodes of bleeding will be evaluated by a central independent adjudication committee (CIAC). Adjudication results will be the basis for the final analyses.
For all children, visits are scheduled at regular time points (see Table 1). Enrolled children who are not treated or those with premature discontinuation of rivaroxaban will at least be seen at the end of the study treatment period. During all contacts, the treatment and clinical course of the child will be evaluated. Children with suspected efficacy or safety outcomes will undergo confirmatory testing as per standard of care. Blood samples for pharmacokinetic (PK)/pharmacodynamics (PD) will be taken at defined time points (see Table 2).
An Independent Data Monitoring Committee (DMC) will monitor the children's safety during the study and give recommendations to the steering committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1
Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.
Time frame: 30 minutes to 1.5 hours post-dose; 2 to 4 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 1 (tid dosing)
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3
Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.
Time frame: 2 to 8 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 3 (tid dosing)
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8
Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.
Time frame: 10 to 16 hours post-dose on Day 8 (bid dosing)
Change From Baseline in Prothrombin Time at Day 1
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.
Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)
Change From Baseline in Prothrombin Time at Day 3
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.
Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)
Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.
Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)
Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.
Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)
Anti-factor Xa Activity (Anti-Xa) Values at Day 1
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
Time frame: 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)
Anti-factor Xa Activity (Anti-Xa) Values at Day 3
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
Time frame: 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)
Anti-factor Xa Activity (Anti-Xa) Values at Day 8
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
Time frame: 10-16 hours post-dose on Day 8 (both bid and tid dosing)
Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events
Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and •associated with a fall in hemoglobin of 2 gram/deciliter (g/dL) or more, •leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or •occurring in a critical site, example: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or •contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: •medical intervention, or •unscheduled contact (visit or telephone call) with a physician, or •cessation (temporary) of study treatment, or •discomfort for the child such as pain
Time frame: From start of study drug administration until 30-day post study treatment period
Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging
Symptomatic recurrence of thromboembolism and asymptomatic deterioration was documented using the appropriate imaging test and confirmed by CIAC which was unaware of treatment assignment. Asymptomatic deterioration in thrombotic burden on repeat imaging, as assessed by the CIAC. Adjudication results were the basis for the final analyses.
Time frame: From start of study drug administration until 30-day post study treatment period
Study was conducted at 9 study centers in 7 countries between 19 November 2015 (first participant first visit) and 18 December 2017 (last participant last visit).
| Milestone | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Started | 5 | 5 |
| Completed | 5 | 4 |
| Not completed | 0 | 1 |
| Withdrew: Withdrew from treatment | 0 | 1 |
Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.
| microgram per liter (mcg/L) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| 30 minutes to 1.5 hours post-dose | 85.2001 ± 37.72 | — |
| 30 minutes to 3 hours post-dose | — | 42.6837 ± 39.35 |
| 2 to 4 hours post-dose | 73.7641 ± 64.38 | — |
| 7 to 8 hours post-dose | — | 12.1027 ± 130.13 |
Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and •associated with a fall in hemoglobin of 2 gram/deciliter (g/dL) or more, •leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or •occurring in a critical site, example: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or •contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: •medical intervention, or •unscheduled contact (visit or telephone call) with a physician, or •cessation (temporary) of study treatment, or •discomfort for the child such as pain
| count of participants | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Major bleeding events | 0 | 0 |
| Clinically relevant non-major bleeding events | 0 | 0 |
Symptomatic recurrence of thromboembolism and asymptomatic deterioration was documented using the appropriate imaging test and confirmed by CIAC which was unaware of treatment assignment. Asymptomatic deterioration in thrombotic burden on repeat imaging, as assessed by the CIAC. Adjudication results were the basis for the final analyses.
| count of participants | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Symptomatic recurrent venous thromboembolism | 0 | 0 |
| Asymptomatic deterioration in thrombotic burden | 0 | 0 |
Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.
| microgram per liter (mcg/L) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| 30 minutes to 3 hours post-dose | — | 32.2879 ± 267.05 |
| 2 to 8 hours post-dose | 102.3285 ± 40.36 | — |
| 7 to 8 hours post-dose | — | 9.1716 ± 160.52 |
Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.
| microgram per liter (mcg/L) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8 | 2.5696 ± 70.82 | NA ± NA |
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.
| seconds (sec) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Change From Baseline in Prothrombin Time at Day 1 | 11.6 ± 17.3 | 0.025 ± 0.714 |
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.
| seconds (sec) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Change From Baseline in Prothrombin Time at Day 3 | 3.74 ± 2.84 | 1.13 ± 2.10 |
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.
| seconds (sec) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1 | 13.6 ± 12.4 | 2.33 ± 5.53 |
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.
| seconds (sec) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3 | 7.02 ± 5.08 | 3.47 ± 7.59 |
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
| microgram per liter (mcg/L) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Anti-factor Xa Activity (Anti-Xa) Values at Day 1 | 63.3 ± 60.8 | 18.0 ± 8.37 |
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
| microgram per liter (mcg/L) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Anti-factor Xa Activity (Anti-Xa) Values at Day 3 | 67.3 ± 48.7 | 59.8 ± 46.8 |
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
| microgram per liter (mcg/L) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Anti-factor Xa Activity (Anti-Xa) Values at Day 8 | 7.25 ± 0.00 | 9.92 ± 5.35 |
Collected over From start of study treatment up to 30 days after the last administration of study drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Rivaroxaban (BAY59-7939) Suspension Tid | 0/5 (0%) | 1/5 (20%) | 0/5 (0%) |
| Event | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| Atrial thrombosisCardiac disorders | 0/5 | 1/5 |
| Event | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid |
|---|---|---|
| VomitingGastrointestinal disorders | 1/5 | 0/5 |
Safety analysis set (SAF) included all participants who received at least one dose of rivaroxaban.
| Age, Continuous(Months) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid | Total |
|---|---|---|---|
| Mean | 1.81 ± 2.24 | 1.12 ± 0.60 | 1.47 ± 1.59 |
| Sex: Female, Male(Participants) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid | Total |
|---|---|---|---|
| Female | 1 | 4 | 5 |
| Male | 4 | 1 | 5 |
| Race/Ethnicity, Customized(Participants) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid | Total |
|---|---|---|---|
| Black or African American | 1 | 0 | 1 |
| White | 3 | 5 | 8 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Weight(Kilogram (kg)) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid | Total |
|---|---|---|---|
| Mean | 4.33 ± 2.19 | 3.70 ± 0.85 | 4.02 ± 1.60 |
| Prothrombin Time(Seconds (sec)) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid | Total |
|---|---|---|---|
| Mean | 13.3 ± 0.378 | 13.9 ± 1.31 | NA ± NA |
| Activated Partial Thromboplastin Time (aPTT)(Seconds (sec)) | Rivaroxaban (BAY59-7939) Suspension Bid | Rivaroxaban (BAY59-7939) Suspension Tid | Total |
|---|---|---|---|
| Mean | 34.0 ± 4.05 | 34.9 ± 2.62 | NA ± NA |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Dec 2017, 24 months.
Results were first posted in Jul 2018, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban